导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -5.20% | 3427/4773 |
| 近一周 | -4.97% | 5264/5465 |
| 近一月 | -2.85% | 1957/5421 |
| 近一季 | -9.89% | 3666/5231 |
| 近半年 | -13.16% | 3866/4920 |
| 近一年 | 19.13% | 603/4394 |
| 近两年 | 107.12% | 574/2954 |
| 近三年 | 76.01% | 288/2253 |
| 成立以来 | 117.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.73% 1198/4961 |
-6.19% 3670/5312 |
- - |
- - |
| 2025 | 93.35% 32/4813 |
10.36% 317/3635 |
5.20% 630/4076 |
43.77% 644/4524 |
15.83% 45/4813 |
| 2024 | 3.75% 1911/3463 |
10.06% 79/2808 |
-5.25% 1676/3014 |
11.65% 2483/3129 |
-10.88% 3003/3463 |
| 2023 | -10.62% 1317/2656 |
5.43% 785/2280 |
-7.78% 1911/2385 |
-4.11% 1061/2515 |
-4.13% 882/2655 |
| 2022 | -19.74% 888/2207 |
-7.37% 240/1919 |
5.77% 828/2016 |
-16.28% 1437/2113 |
-2.15% 1778/2208 |
| 2021 | 32.87% 54/1822 |
0.21% 308/1255 |
10.96% 415/1330 |
21.69% 39/1466 |
-1.80% 1389/1822 |
| 2020 | 36.64% 389/1250 |
-12.55% 891/1028 |
11.53% 726/1067 |
7.47% 779/1164 |
30.36% 19/1184 |
| 2019 | 27.32% 549/1092 |
20.03% 614/754 |
-2.53% 355/804 |
-3.20% 731/850 |
12.43% 35/918 |
| 2018 | -37.74% 602/834 |
- - |
- - |
- - |
-13.15% 510/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证申万有色金属ETF发起联接A VS. 长安沪深300非周期A(740101) |